Teva and Nuvelution partner on Tourette drug development
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches :: Scrip
ADDING MULTIMEDIA Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ (albuterol sulfate 117 mcg) Inhalation Powder | Business Wire
Teva Pharmaceuticals and IBM Expand Global Partnership to Enable Drug Development and Chronic Disease Management with
Plant issues plague Celltrion and Teva as FDA issues two biosimilars CRLs
Teva
TEVA | Market Realist
A Look at Teva's Generic Drugs Research Pipeline
Teva, chasing Amgen's Aimovig, scores much-needed FDA approval for migraine drug Ajovy | Fierce Pharma
Teva Pharmaceuticals Near 20-Year Lows (NYSE:TEVA) | Seeking Alpha
Generic NSCLC treatment launched by Teva
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets | Business Wire
Refreshing the biologic pipeline 2020 | Nature Biotechnology
EX-99.1
Teva's pursuit of J&J boosted by FDA acceptance of filing for approval of long-acting schizophrenia drug | Fierce Pharma
TEVA | Market Realist
Generic Drugs in the Pipeline: 2017 Update
Teva
Teva Pharmaceutical Industries Ltd (TEVA) - Product Pipeline Analysis, 2021 Update
EX-99.1
Teva: Definitely Undervalued (NYSE:TEVA) | Seeking Alpha
Teva's AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults | Business Wire
Sosei see Teva pipeline cull as an opportunity | pharmaphorum
Berkovish Branding & Web Design Studio.
Teva Stock Offers Maximum Optimism For Investors (NYSE:TEVA) | Seeking Alpha
Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington's Disease — Hereditary Neurological Disease Centre
